公开(公告)号：US20220091136A1

公开(公告)日：2022-03-24

申请号：US17475753

申请日：2021-09-15

Applicant: AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION

Inventor： You-Sun KIM ,  Siyoung YANG

IPC: G01N33/68

Abstract: Disclosed is the novel use of TRIM24 and RIP3 as biomarkers for diagnosing osteoarthritis, in which it is first identified that TRIM24 and RIP3 can be used as biomarkers for diagnosing osteoarthritis by confirming the tendency of TRIM24 expression to decrease and RIP3 expression to increase at the onset of osteoarthritis. These two proteins are useful in confirming the change in the expression level from the onset of osteoarthritis, thus enabling early diagnosis of osteoarthritis and effectively blocking the progression of osteoarthritis at an early stage.

公开(公告)号：US20190030054A1

公开(公告)日：2019-01-31

申请号：US16130522

申请日：2018-09-13

Applicant: AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION

Inventor： Siyoung YANG ,  Jimin JEON ,  Li-Jung KANG ,  Chanmi CHO

IPC: A61K31/702 ,  A61P19/02 ,  A61P17/00

Abstract: Provided are a composition for inhibiting immune cell proliferation, including sialyllactose or a derivative thereof as an active ingredient, and a method of inhibiting immune cell proliferation, wherein the composition and the method may decrease expression of chemokines, decrease expression of pro-inflammatory cytokines, decrease production of inflammatory mediators, decrease expression of COX2, and decrease production of PEG2, and therefore, may be useful for the prevention or treatment of atopic dermatitis or arthritis.

公开(公告)号：US20230047431A1

公开(公告)日：2023-02-16

申请号：US17880269

申请日：2022-08-03

Applicant: AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION

Inventor： Siyoung YANG

IPC: G01N33/68 ,  G01N33/50 ,  A61P19/02 ,  A61K31/7088

Abstract: The present disclosure relates to a composition for treating or diagnosing osteoarthritis targeting activin A receptor type 2B (ACVR2B). More specifically, the present disclosure provides ACVR2B as a biomarker for diagnosing osteoarthritis because it was found that expression and activity of ACVR2B were increased at an early stage of osteoarthritis, expression of Mmp3, Mmp13, and Cox2 that induce destruction of cartilage was increased thereby, and expression of the genes was suppressed by inhibition of ACVR2B expression. In addition, since it was found that osteoarthritis was alleviated by suppressing the expression of ACVR2B, the present disclosure provides an ACVR2B expression or activity inhibitor as a therapeutic agent for osteoarthritis.